Globus Medical (NYSE:GMED – Get Free Report) released its quarterly earnings results on Tuesday. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18, Briefing.com reports. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The business had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. During the same period in the previous year, the business posted $0.57 earnings per share. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. Globus Medical updated its FY24 guidance to $2.90-3.00 EPS and its FY 2024 guidance to 2.900-3.000 EPS.
Globus Medical Trading Down 0.9 %
Globus Medical stock opened at $81.97 on Friday. The firm has a market capitalization of $11.10 billion, a P/E ratio of 273.23, a PEG ratio of 2.06 and a beta of 1.17. Globus Medical has a 1 year low of $43.38 and a 1 year high of $84.87. The business has a 50-day moving average of $71.92 and a 200-day moving average of $68.16.
Insider Transactions at Globus Medical
In related news, Director David D. Davidar sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total value of $2,251,200.00. Following the completion of the transaction, the director now directly owns 536,275 shares in the company, valued at approximately $40,242,076. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director David D. Davidar sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total value of $2,251,200.00. Following the completion of the transaction, the director now directly owns 536,275 shares in the company, valued at approximately $40,242,076. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $70.36, for a total value of $1,055,400.00. Following the completion of the transaction, the director now owns 42,884 shares of the company’s stock, valued at $3,017,318.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.54% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on GMED
About Globus Medical
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
Further Reading
- Five stocks we like better than Globus Medical
- What is Put Option Volume?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- Insider Buying Explained: What Investors Need to Know
- L3Harris: Positioned for Gains With Trump’s Defense Policies
- What is the Euro STOXX 50 Index?
- Is First Solar’s Earnings Drop a Golden Buying Opportunity?
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.